Groupe Berkem reports revenues of $56.6 million for full 2022

In France, biobased chemistry company Groupe Berkem, reported revenues of $56.6 million for full 2022, up 12.4% compared to the previous year. The Group’s business recorded revenue of $13.6 million in the fourth quarter of 2022, representing an increase of 26.3% compared to the same period in 2021. Olivier Fahy, Chairman and Chief Executive Officer of the Groupe Berkem, said: “Despite the 2022 financial year being marked by an inflationary context and persistent geopolitical tensions, Groupe Berkem managed to stay on course and continue its growth dynamic, on track to achieve its 2024 objectives. This was made possible by strategic investments, in particular in Lixol, which recorded a good performance over the entire period. In addition, in the fourth quarter, we strengthened our international coverage by joining forces with the Barentz group, which now distributes our ingredients in North America as well as in Germany, Austria and German-speaking Switzerland.” The Group confirmed its ambition to achieve revenue of at least $71 million by 2024.

More on the story.